Phathom Pharmaceuticals shares soar on FDA exclusivity grant

June 07, 2025 03:03 AM AEST | By Investing

Google News:

Phathom Pharmaceuticals shares soar on FDA exclusivity grant — Image source: Kalkine Media

Recent News

Populous Acquires Fentress Architects, Expanding Global Aviation Portf...

Carney launches ‘One Canadian Economy’ Act to unify trade, approvals

Trump signs orders to enhance drone defenses, support supersonic trave...

US job growth in May tops forecasts, but Macquarie warns cracks are em...

Investing.com -- Shares of Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) soared 128% after the FDA granted the company’s petition for exclusivity in the Orange Book listing for its drug Voquezna (vonoprazan fumarate). The decision by the Food and Drug Administration to extend the exclusivity period to a full 10 years for Voquezna, under the umbrella of the Generating Antibiotic Incentives Now (GAIN) provisions, has been a significant catalyst for the stock’s movement.

The FDA’s response to Phathom’s citizen petition, which was received on December 11, 2024, allows the company to benefit from the extended exclusivity initially granted to Voquezna Triple Pak and Voquezna Dual Pak. These packages, which contain the new chemical entity (NCE) vonoprazan, were designated as qualified infectious disease products (QIDPs) and received an additional 5 years of exclusivity, totaling 10 years under the GAIN provisions. The FDA’s decision is in line with its umbrella policy, which aims to encourage the development and improvement of drugs containing the NCE without compromising the innovator’s exclusivity period.

This FDA ruling is pivotal for Phathom as it ensures that Voquezna will benefit from the remainder of the NCE exclusivity recognized for the Voquezna Paks. The Orange Book will be updated to accurately reflect this extended period of exclusivity, which is a substantial win for the company. This exclusivity extension is particularly important as it protects Voquezna from generic competition and allows Phathom to capitalize on the market potential of its product without immediate threats.

This article first appeared in Investing.com

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.